In conclusion, the successful treatment of our melanoma patient with peritoneal metastases using L-XRT in conjunction with anti-PD1 therapy highlights the potential of integrating radiotherapy with immunotherapy to overcome resistance and achieve durable responses. This evidence concerns the gene PDCD1 and melanoma.